Recruitment Update

All you need for recruiting participants to BSRBR-RA can be found on our registration page.

Whether your patient is new to the register or already participating; there is a guide to which drugs we are currently recruiting (including the latest adalimumab biosimilars) and all the forms and documents you will need for both new or re-registrations.

Registering patinets

If you still have questions about eligibility and recruitment please contact us.

Drug Names: Recording Therapy Changes

What’s in a name?

Recording therapy changes at Clinical Follow Up

drugnames

With many biosimilars on the market we would like to remind you of the importance of using the drug trade names when completing clinical follow up.  Without the trade name it makes it difficult for us to get a full picture of the patient’s treatment history, including knowing which drug they were on at the time of any adverse event.

fup drug eg

Dates of changes are also important, please let us know the date of the last dose of the previous drug as well as the new start date.  We understand this can be difficult if the patient is starting a new prescription via home delivery or has an old prescription that needs to be used first, but even a month and year can be useful to us rather than a missing date.

If you really can’t get you hands on the information please let us know by making a note on the form so that we do not repeatedly contact you for missing information.

We really appreciate all the details that you provide us with, thank you.

Recruitment News

Find all the information you need for recruiting participants with the BSRBR-RA on our registration page.

Whether your patient is new to the register or already participating. There are guides to what drugs we are currently recruiting for, along with all the forms and documents you will need, for new or re-registrations.

Registering patinets

If you still have questions about eligibility and recruitment please contact us.

BSRBR-RA Publication News

Wondering where all that data we collect goes?  Have a look at the newest publications using BSRBR-RA data:

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register

There are also lay summaries available for many of our publications which provide a more accessible overview.  Lay summaries and details of BSRBR-RA publications can be found on our research page.